Guggenheim More Than Doubles Erasca (ERAS) PT Following Clinical Progress and Updated Pipeline Models

Erasca Inc. (NASDAQ:ERAS) is one of the new stocks on the rise. On January 27, Guggenheim increased its price target for Erasca from $5 to $12 with a Buy rating. This decision followed a model update that accounted for recent clinical developments and fresh financing. The firm’s revised valuation includes risk-adjusted revenue estimates for the candidate ERAS-0015, assigning it a 30% probability of success in treating second-line or later NSCLC and PDAC. These projections are centered on an anticipated com ...